Study concept and design: Prey, Voisard, Léauté-Labrèze.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Prey, Taïeb, Léauté-Labrèze, Ezzedine.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Prey, Ezzedine.
Administrative, technical, or material support: Prey, Voisard, Delarue, Lebbe, Taïeb, Léauté-Labrèze.
Study supervision: Prey, Voisard, Taïeb, Léauté-Labrèze, Ezzedine.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Prey and Leaute-Labreze reported being investigators in clinical trials evaluating propranolol in infantile hemangioma promoted by Pierre Fabre Dermatologie pharmaceutical company. No other disclosures were reported.
Funding/Support: This study was supported by Pierre Fabre Dermatologie pharmaceutical company and the French Health Products Agency. The pharmaceutical company developed and provided the oral pediatric specific formulation of propranolol chlorhydrate.
Role of the Funder/Sponsor: Pierre Fabre Dermatologie pharmaceutical company and the French Health Products Agency had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Valérie Ortis, MD (Laboratoire Pierre Fabre Dermatologie, Lavaur, France), for coordinating the French Compassionate Use Program, in particular checking inclusion criteria and collection of vigilance data, and Sarah Tilly, MS (Scinopsis, Frejus, France), for reviewing the manuscript. Both were compensated.